Susquehanna International Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-16,000
| Closed | -$21K | – | 10939 |
|
|
2017
Q4 | $21K | Sell |
16,000
-23,800
| -60% | -$38.7K | ﹤0.01% | 9062 |
|
|
2017
Q3 | $84K | Sell |
39,800
-33,600
| -46% | -$82K | ﹤0.01% | 8421 |
|
|
2017
Q2 | $213K | Buy |
73,400
+34,500
| +89% | +$103K | ﹤0.01% | 8192 |
|
|
2017
Q1 | $134K | Buy |
+38,900
| New | +$154K | ﹤0.01% | 8263 |
|
|
2016
Q3 | – | Sell |
-1,250
| Closed | -$5K | – | 9721 |
|
|
2016
Q2 | $5K | Sell |
1,250
-210
| -14% | -$949 | ﹤0.01% | 8443 |
|
|
2016
Q1 | $8K | Sell |
1,460
-9,060
| -86% | -$118K | ﹤0.01% | 8896 |
|
|
2015
Q4 | $181K | Sell |
10,520
-27,250
| -72% | -$650K | ﹤0.01% | 8508 |
|
|
2015
Q3 | $797K | Sell |
37,770
-4,350
| -10% | -$149K | ﹤0.01% | 6214 |
|
|
2015
Q2 | $2.08M | Buy |
42,120
+28,910
| +219% | +$1.73M | ﹤0.01% | 4626 |
|
|
2015
Q1 | $1.03M | Sell |
13,210
-20,730
| -61% | -$1.29M | ﹤0.01% | 5702 |
|
|
2014
Q4 | $2.06M | Sell |
33,940
-18,650
| -35% | -$937K | ﹤0.01% | 4414 |
|
|
2014
Q3 | $2.24M | Sell |
52,590
-2,420
| -4% | -$130K | ﹤0.01% | 4397 |
|
|
2014
Q2 | $3.4M | Buy |
55,010
+6,960
| +14% | +$405K | ﹤0.01% | 3690 |
|
|
2014
Q1 | $3.12M | Buy |
48,050
+1,100
| +2% | +$74.4K | ﹤0.01% | 3587 |
|
|
2013
Q4 | $2.64M | Sell |
46,950
-6,040
| -11% | -$339K | ﹤0.01% | 3824 |
|
|
2013
Q3 | $3.25M | Buy |
52,990
+10,350
| +24% | +$701K | ﹤0.01% | 3358 |
|
|
2013
Q2 | $2.5M | Buy |
+42,640
| New | +$2.62M | ﹤0.01% | 3570 |
|
Other funds holding OREX
Susquehanna International Group's OREX Position: Q2 2018 in Review
Susquehanna International Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 88,896 shares — an estimated $18K sold.
Susquehanna International Group first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $7.16M in Q2 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Susquehanna International Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Susquehanna International Group sold 88,896 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $18K.
- Susquehanna International Group first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
- Susquehanna International Group's Orexigen Therapeutics, Inc. position peaked at $7.16M in Q2 2014.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.